Full-Time

Finance Manager

External Reporting

Posted on 10/22/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Senior

Remote in USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Requirements
  • Bachelor’s degree in accounting, finance, or a related field.
  • CPA or CA certification preferred.
  • Minimum of 7-10 years of experience in accounting or finance roles with a strong focus on ASX and SEC reporting and compliance.
  • Extensive experience in preparing and filing Annual and quarterly reports to the ASX and NASDAQ, including Form 10-K, Form 10-Q, and Form 8-K.
  • Experience with IFRS and US GAAP financial statement preparation, including reconciliations between US GAAP and IFRS.
  • Proven track record of working in publicly traded companies, preferably with experience in a NASDAQ-listed company.
  • Significant experience in coordinating with external auditors, particularly under PCAOB standards.
  • In-depth knowledge of revenue recognition standards under both US GAAP (ASC 606) and IFRS (IFRS 15).
Responsibilities
  • Responsible for coordinating successful annual, half-yearly and quarterly financial reports for the ASX, NASDAQ (e.g. Form 10-K and Form 10-Q filings), and other local jurisdictions as required by law.
  • Lead the preparation of earnings releases and results presentations.
  • Lead the adoption of newly enacted, and the evaluation of proposed changes to, IFRS and FASB pronouncements or ASX and SEC rules related to disclosures in our financial reports, Form 10-K and Form 10-Q filings.
  • Lead the process for responding to ASIC and SEC comment letters.
  • Provide technical accounting guidance on complex transactions, including revenue recognition, business combinations, leases, impairments, and other critical areas under IFRS and US GAAP.
  • Research and implement new IFRS and FASB standards, advising the business on accounting implications and appropriate accounting treatments.
  • Serve as a subject matter expert on accounting issues related to acquisitions, divestitures, and other significant transactions.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products aim to enhance treatment decisions and offer personalized therapy for conditions that lack effective solutions. The company focuses on areas such as prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a global supply chain to manufacture and distribute its specialized products to healthcare providers and patients. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The goal of Telix Pharmaceuticals is to improve the quality of life for patients by providing advanced diagnostic and therapeutic options.

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

19%

1 year growth

41%

2 year growth

105%
Simplify Jobs

Simplify's Take

What believers are saying

  • Telix's completion of the BLA submission for TLX250-CDx positions it for potential market leadership in kidney cancer imaging.
  • Positive data from the ProstACT SELECT trial for TLX591 indicates promising efficacy in prostate cancer treatment, enhancing the company's therapeutic portfolio.
  • The FDA Fast Track designation for TLX101-CDx for glioma imaging accelerates its path to market, potentially improving outcomes for brain cancer patients.

What critics are saying

  • The recent withdrawal of its IPO due to unfavorable market conditions may impact Telix's financial flexibility and investor confidence.
  • The competitive landscape in biopharmaceuticals, especially in oncology, requires continuous innovation to maintain market position.

What makes Telix Pharmaceuticals unique

  • Telix Pharmaceuticals specializes in targeted radiation therapies, setting it apart from traditional biopharmaceutical companies that may not focus on this innovative approach.
  • The company's robust global supply chain ensures the availability and delivery of its products worldwide, providing a competitive edge in distribution and accessibility.
  • Telix's commitment to sustainability and ethical practices integrates patient care and environmental responsibility into its operations, distinguishing it from competitors.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE